A Pharmacogenetic versus a Clinical Algorithm for Warfarin Dosing
Top Cited Papers
- 12 December 2013
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 369 (24), 2283-2293
- https://doi.org/10.1056/nejmoa1310669
Abstract
The clinical utility of genotype-guided (pharmacogenetically based) dosing of warfarin has been tested only in small clinical trials or observational studies, with equivocal results. We randomly assigned 1015 patients to receive doses of warfarin during the first 5 days of therapy that were determined according to a dosing algorithm that included both clinical variables and genotype data or to one that included clinical variables only. All patients and clinicians were unaware of the dose of warfarin during the first 4 weeks of therapy. The primary outcome was the percentage of time that the international normalized ratio (INR) was in the therapeutic range from day 4 or 5 through day 28 of therapy. At 4 weeks, the mean percentage of time in the therapeutic range was 45.2% in the genotype-guided group and 45.4% in the clinically guided group (adjusted mean difference, [genotype-guided group minus clinically guided group], -0.2; 95% confidence interval, -3.4 to 3.1; P=0.91). There also was no significant between-group difference among patients with a predicted dose difference between the two algorithms of 1 mg per day or more. There was, however, a significant interaction between dosing strategy and race (P=0.003). Among black patients, the mean percentage of time in the therapeutic range was less in the genotype-guided group than in the clinically guided group. The rates of the combined outcome of any INR of 4 or more, major bleeding, or thromboembolism did not differ significantly according to dosing strategy. Genotype-guided dosing of warfarin did not improve anticoagulation control during the first 4 weeks of therapy. (Funded by the National Heart, Lung, and Blood Institute and others; COAG ClinicalTrials.gov number, NCT00839657.).This publication has 27 references indexed in Scilit:
- Pharmacogenetic warfarin dose refinements remain significantly influenced by genetic factors after one week of therapyThrombosis and Haemostasis, 2012
- Genetics informatics trial (GIFT) of warfarin to prevent deep vein thrombosis (DVT): rationale and study designThe Pharmacogenomics Journal, 2011
- Statistical design of personalized medicine interventions: The Clarification of Optimal Anticoagulation through Genetics (COAG) trialTrials, 2010
- Prospective alpha allocation in the clarification of optimal anticoagulation through genetics (COAG) trialClinical Trials, 2010
- Integration of Genetic, Clinical, and INR Data to Refine Warfarin DosingClinical Pharmacology & Therapeutics, 2010
- Debating Clinical UtilityPublic Health Genomics, 2010
- Estimation of the Warfarin Dose with Clinical and Pharmacogenetic DataNew England Journal of Medicine, 2009
- A genome-wide scan for common genetic variants with a large influence on warfarin maintenance doseBlood, 2008
- Dosing Algorithms to Predict Warfarin Maintenance Dose in Caucasians and African AmericansClinical Pharmacology & Therapeutics, 2008
- Use of Pharmacogenetic and Clinical Factors to Predict the Therapeutic Dose of WarfarinClinical Pharmacology & Therapeutics, 2008